louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00743600: Ultrasound Evaluation of the Rotator Cable and Associated Structures.
Official title: Ultrasound Evaluation of the Rotator Cable and Associated Structures.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Shoulder Pain
Keywords: ultrasound
rotator cuff
Lead sponsor: University of Michigan
Sponsor class: OTHER
First posted: 2008-08-29
Enrollment: 123
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This study will use healthy volunteers and patients with shoulder problems (pain or impaired movement). Ultrasound will be used to image and document the appearance of both normal and abnormal shoulder structures.

Detailed description: The purpose of this study is to document normal and abnormal appearances of various shoulder structures (rotator cable and rotator cuff).

This study will recruit healthy volunteers and patients who have been referred to Radiology for a symptomatic shoulder (a shoulder that is causing the patient pain, or is limited in its ability to move.) Both groups will undergo ultrasound imaging of the shoulder.

Eligibility criteria: Inclusion Criteria:

* Patients with shoulder pain referred to radiology for ultrasound of shoulder

Exclusion Criteria:

* Patients less than 18 years of age

Primary outcomes:
measure: To determine if Ultrasound can identify the rotator cable and the associated structures.
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: University of Michigan Health System
state: Michigan
Study officials:
affiliation: UM
name: Yoav Morag, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06260800: Spanish Version of Credibility and Expectancy Questionnaire in Patients with Musculoskeletal Injuries
Official title: Translation, Adaptation and Valitation of the Spanish Version of Credibility and Expectancy Questionnaire in Patiens with Musculoskeletal Injuries
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Validation Study
Lead sponsor: University of Valladolid
Sponsor class: OTHER
First posted: 2024-02-15
Enrollment: 76
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Patients who are going to start physiotherapy treatment due to musculoskeletal injuries.

Brief summary: Physiotherapy treatment of musculoskeletal injuries should be performed following the main clinical guidelines of person-centered care. Patients' perception of the abilities and facilities provided by physiotherapists boost a convenient therapeutic relationship. This relation is linked with more satisfaction and adherence during the treatment, as well as credibility and expectancy of the patient related to the treatment. Thus, Credibility and Expectancy questionnaire is normally used to assess that point. CEQ presents good psychometric properties when used in Physisiotherapy interventions, but there is not a spanish version of this questionaire.


Eligibility criteria: Inclusion Criteria:

* Volunteer patients who are going to start physiotherapy treatment due to musculoskeletal injuries.
* Age above 18 years old.
* Understanding of the study purpose and signing the informed consent.

Exclusion Criteria:

* Patients with cognitive deprivation.
* Not able to fill in the questionnaires autonomously.
* Mother tongue different from Spanish.

Primary outcomes:
measure: Content validity
timeFrame: During the intervention: Session 1 and 2 treatment
measure: Construct validity
timeFrame: During the intervention: session 1 and 2 treatment
measure: Reliability
timeFrame: During the intervention: Session 1 and 2 treatment
measure: Criterion validity
timeFrame: During the intervention: session 1 and 4 treatment.
Secondary outcomes:
Other outcomes:
Locations:
city: Soria
country: Spain
facility: Silvia Lahuerta Martín
Study officials:
affiliation: University of Valladolid, Soria, Spain
name: Silvia Lahuerta Martín
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01370200: Regional Citrate Anticoagulation in Plasma Exchange Treatment
Official title: Regional Citrate Anticoagulation in Plasma Exchange Treatment
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Focal Segmental Glomerulosclerosis
Guillain-Barre Syndrome
Keywords: citrate
anticoagulation
plasma exchange
efficacy
Lead sponsor: University Medical Centre Ljubljana
Sponsor class: OTHER
First posted: 2011-06-09
Enrollment: 140
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators want to compare the efficacy of plasma exchange treatment with using two different citrates ( 4% and 15% ) as anticoagulants in plasma exchange treatment.

The efficacy of plasma exchange treatment is better with using 15% trisodium citrate as anticoagulant during the plasma exchange procedure.

Detailed description: To compare the elimination rate of immunoglobulins in plasma exchange treatment by using two differently concentrated citrates for anticoagulation during plasma exchange procedure. At the same time we want to compare acid-base , electrolyte status and anticoagulation protocol in two citrate groups.

Eligibility criteria: Inclusion Criteria:

* patients who need plasma exchange treatment
* human albumins as a replacement fluid

Exclusion Criteria:

* anemia Hb less than 90

Primary outcomes:
measure: The efficacy of plasma exchange, measuring immunoglobulins type G before and after the procedure, using 4% and 15% citrate as anticoagulants
timeFrame: the whole trial, approximately 3 years
Secondary outcomes:
measure: The percentage of patients in whom there is a 50% reduction of immunoglobulins after plasma exchange using 4% and 15% citrate as anticoagulants
timeFrame: the whole trial, approximately 3 years
measure: Using 15% citrate as an anticoagulant during plasma exchange treatment is as safe as using 4% citrate as anticoagulant during plasma exchange treatment.
timeFrame: the whole trial, approximately 3 years
Other outcomes:
Locations:
city: Ljubljana
country: Slovenia
facility: Center for acute and complicated dialysis, Clinical department of nephrology, UMC Ljubljana
Study officials:
affiliation: Center for acute and complicated dialysis, UMCLjubljana
name: Manja Antonič, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Antonic M, Gubensek J, Buturovic-Ponikvar J, Ponikvar R. Comparison of citrate anticoagulation during plasma exchange with different replacement solutions. Ther Apher Dial. 2009 Aug;13(4):322-6. doi: 10.1111/j.1744-9987.2009.00733.x.
Clinical trial NCT05484700: Antibodies and Immunity After Vaccination of Recovered Patients With COVID-19 and Long COVID-19 Symptoms
Official title: SARS-CoV-2 Neutralizing Antibodies and Immunity After Vaccination of Recovered Patients With COVID-19 and Correlation With Immunity and Long-COVID-19 Symptoms
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Long COVID-19
Keywords: Long COVID-19
antibody responsibility
immunogenicity
Lead sponsor: Mahidol University
Sponsor class: OTHER
First posted: 2022-08-02
Enrollment: 305
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The COVID-19 patients who confirmed SARS-CoV-2 infection from January to May 2022 (during the Omicron wave), and post COVID-19 they had not received any additional COVID vaccine.

Brief summary: We investigated the association between immune system responsibilities in Long COVID patients and Full recovery patients.

Detailed description: This retrospective cohort study compared immunogenicity post COVID-19 between individuals (aged 18-65 years and had confirmed SARS-CoV-2 infection from January to May 2022 ) with residual Long COVID-19 symptoms (LC) and ones with full recovery (Full) related to pathophysiology, immunology and clinical consequence.

Eligibility criteria: Inclusion Criteria:

* Long COVID group; at longer than 1-month post COVID-19 based the presence of one of the three following symptoms: fatigue/myalgia, breathlessness, and anorexia
* Full recovery group; patients with asymptomatic symptoms
* post COVID-19 they had not received any additional COVID vaccine

Exclusion Criteria:

* people who received additional vaccination after leaving quarantine before the day of the immunization test
* pregnant patients,
* people who had a history of allergic reactions after COVID-19 vaccination or any drugs

Primary outcomes:
measure: Anti-SARS-CoV-2 RBD IgG
timeFrame: Baseline
measure: Anti-SARS-CoV-2 NP
timeFrame: Baseline
measure: Microneutralization assays
timeFrame: Baseline
Secondary outcomes:
measure: Number of vaccine injection
timeFrame: Baseline
measure: Prevalence of Long COVID-19 symptoms
timeFrame: Baseline
Other outcomes:
Locations:
city: Bangkok Noi
country: Thailand
facility: Faculty of Medicine Siriraj Hospital, Mahidol University
state: Bangkok
Study officials:
affiliation: Doctor in Family Medicine
name: Korapat Mayurasakorn, MD.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02078700: Feasibility of an Early Palliative Care Intervention for Metastatic Cancer Patients. A Phase 2 Study.
Official title: Feasibility of an Early Palliative Care Intervention for Metastatic Cancer Patients. A Phase 2 Study.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Lung Cancer
Mesothelioma
Pancreas Cancer
Gastric Cancer
Keywords: cancer
early palliative care
feasibility
Lead sponsor: Azienda USL Reggio Emilia - IRCCS
Sponsor class: OTHER_GOV
First posted: 2014-03-05
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: The objective of this phase 2 study is to evaluate the feasibility of an early palliative care intervention for metastatic cancer patients. Feasibility will be assessed in terms of percentage of patients that accept the proposal of the early palliative care intervention and that effectively start to be followed in the palliative care out-patient clinic. The study will be performed in a consecutive series of newly diagnosed patients affected by lung cancer (NSCLC or SCLC, stage IIIb, IV), mesothelioma (stage II, IV), pancreas (stage IV), stomach (stage IIIb-IV).


Eligibility criteria: Inclusion Criteria:

* patients within 8 weeks of cancer diagnosis confirmed by histology or cytology
* lung cancer (NSCLC or SCLC) stage IIIb-IV OR mesothelioma stage III-IV OR pancreas cancer stage IV, OR gastric cancer stage IIIb-IV
* age more than 18 years
* performance status (ECOG) ≤ 2;
* ability to read, understand and fill-in the questionnaires
* written informed consent to the study

Exclusion Criteria:

* any chemotherapy, radiotherapy or ormonotherapy for any tumour in the past 12 months

Primary outcomes:
measure: percentage of cancer patients that accept and attend the early palliative care programme
timeFrame: up to 30 days after the diagnosis of cancer
Secondary outcomes:
measure: percentage of cancer patients that receive the proposal of early palliative by the oncologists-pneumologists
timeFrame: up to 30 days after the diagnosis of cancer
Other outcomes:
Locations:
city: Reggio Emilia
country: Italy
facility: IRCCS Arcispedale S.Maria Nuova
Study officials:
References:
citation: Costantini M, Apolone G, Tanzi S, Falco F, Rondini E, Guberti M, Fanello S, Cavuto S, Savoldi L, Piro R, Mecugni D, Di Leo S. Is early integration of palliative care feasible and acceptable for advanced respiratory and gastrointestinal cancer patients? A phase 2 mixed-methods study. Palliat Med. 2018 Jan;32(1):46-58. doi: 10.1177/0269216317731571. Epub 2017 Sep 27.
Clinical trial NCT06367400: Validation of Pediatric Sleep Questionnaire on a Swedish Cohort
Official title: Validation of Pediatric Sleep Questionnaire, a Multi-center Study in Sweden
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Obstructive Sleep Apnea
Sleep Disorder
Sleep Disorders in Children
Obstructive Sleep Apnea of Child
Keywords: OSDB
PSQ
Pediatrics
Lead sponsor: Uppsala University
Sponsor class: OTHER
Collaborators: name: Karolinska Institutet
name: Örebro University, Sweden
name: Umeå University
name: Göteborg University
First posted: 2024-04-16
Enrollment: 520
Sex: ALL
Minimum age (years): 18
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population will be included from the ENT-clinics or the waiting lists to surgical treatments.

Brief summary: This study is aimed to validate the questionnaire called Pediatric Sleep Questionnaire on a Swedish cohort of children from 18 months to 15 years old with obstructive sleep disordered breathing.


Eligibility criteria: Inclusion Criteria:

* Children with OSDB-symptoms referred to ENT-clinics
* Age between 18 months and 15 years old.
* Good knowledge of the Swedish language

Exclusion Criteria:

* Craniofacial abnormalities
* Mb Down
* neuromuscular disorders
* do not understand swedish

Primary outcomes:
measure: Level of baseline PSQ
timeFrame: Baseline
measure: Changes of baseline PSQ after treatment
timeFrame: 6 months to 12 months
Secondary outcomes:
measure: PSQ vs OSA-18
timeFrame: 6 months
measure: PSQ vs. PSG
timeFrame: 6 months
measure: PSQ levels of healthy controls vs children with OSDB
timeFrame: 6 months
Other outcomes:
measure: 5 and 10 years follow-up
timeFrame: 11 years
Locations:
city: Uppsala
country: Sweden
facility: Akademiska hospital
Study officials:
References:
Clinical trial NCT01763775: Clinical Trial of Transtek Body Fat Analyzer (GBF-1251-B & Other 3 Models)
Official title: Verify the Functions and Efficiency of Transtek (Trade Mark) Body Fat Analyzer, GBF-1251-B, BF-1255-B, BF-1256-B, and GBF-1257-B
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Weight
Body Fat Disorder
Bone Mass
Keywords: weight
total body water
body fat
muscle mass
bone mass
Lead sponsor: BTS International
Sponsor class: OTHER
Collaborators: name: West China Hospital
First posted: 2013-01-09
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: FACTORIAL

Brief summary: The clinical protocol of the clinical testing of this device:

1. Objective of the test: To verify the functions and efficiency of devices.
2. Test methods and procedures: Comparison Test.
3. Device Under Test (DUT): Transtek Body Fat Analyzer, Model: GBF-1251-B, BF-1255-B, BF-1256-B, and GBF-1257-B.
4. Comparison device: Transtek, Glass Body Fat Analyzer, GBF-950-D.
5. Study endpoints: DUT and the comparison device are substantial equivalence.
6. Statistical methodology used: Description of statistical methods.

Detailed description: 1. Test Purpose:

   The aim of clinical test is to collect weight, body fat, total body water, bone mass, and muscle mass reading value which measured by DUT and reference device.
2. Target Subject:

   The subject database shall contain at least 25 male and 25 female subjects and all above 18 years old.
3. Test procedures:

   1. Record the name, age, gender, and height of each subject.
   2. Let subject seated calmly for two minutes before test, dry the feet.
   3. Use device to measure weight, body fat, total body water, bone mass, and muscle mass; record reading value.
   4. For each subject, repeat 3) to get 3 pairs measurements.
   5. Repeat step 1) to 4) for every device (DUT: GBF-1251-B, BF-1255-B, BF-1256-B, and GBF-1257-B; and reference device: GBF-950-D).
   6. Repeat step 1) to 5) for each subject.
4. Note:

   1. No motion and speaking are allowed during the measurement.
   2. All DUT use the same algorithms and contact the patient at the same body locations (feet), and operate on the same frequency.
   3. Test environment: Temperature: 22±1℃; Relative humidity: 40\~70%.

Eligibility criteria: Inclusion Criteria:

* male,female

Exclusion Criteria:

* below 18 years old

Primary outcomes:
measure: BMI (Body Mass Index)
timeFrame: 5 Day
Secondary outcomes:
measure: Weight
timeFrame: 5 Days
Other outcomes:
Locations:
city: Chengdu
country: China
facility: Wuhou District Hospital
state: Sichuan
Study officials:
affiliation: Wuhou District Hospital
name: Guoqing Li, Director
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03278275: PET/CT Imaging of uPAR-expression in Patients With Neuroendocrine Tumors Using 68Ga-NOTA-AE105
Official title: PET/CT Imaging of uPAR-expression in Patients With Neuroendocrine Tumors Using 68Ga-NOTA-AE105
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Neuroendocrine Tumors
Keywords: urokinase plasminogen activator receptor
uPAR PET/CT
positron emission tomography
neuroendocrine tumors
Lead sponsor: Rigshospitalet, Denmark
Sponsor class: OTHER
First posted: 2017-09-11
Enrollment: 116
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The aim of this non-randomised, prospective study is to investigate the applicability and prognostic value of uPAR PET/CT with the radioligand 68Ga-NOTA-AE105 in patients with neuroendocrine tumors (NETs).

Detailed description: 68Ga-NOTA-AE105 is a radioligand targeting urokinase plasminogen activator receptor (uPAR), which is a promising imaging biomarker of tumor aggressiveness. A total of 120 NET patients will be subjected to a uPAR-PET/CT scan. Follow-up will be performed (from the time of the angiogenesis PET/ CT) at 6 months for disease specific survival (DSS) and a 1 year follow-up for PFS and OS. The uptake of 68Ga-NOTA-AE105 in tumor lesions will be quantified as Standardized Uptake Values (SUVmax/SUVmean) and compared with PFS, DSS and OS (dichotomized above/below median SUVmax and analyzed by Kaplan-Meier)

Eligibility criteria: Inclusion Criteria:

* Diagnosed with gastro-entero-pancreatic Neuroendocrine Tumors (GEP-NET; grade: G1-G3) or broncho-pulmonary NET.
* WHO performance status 0-2
* Must be able to read and understand the patient information in Danish and to give informed consent

Exclusion Criteria:

* Pregnancy
* Breast-feeding
* Weight more than the maximum weight limit for the PET/CT bed of the scanner (140 kg)
* History of allergic reaction attributable to compounds of similar chemical or biologic composition to 68Ga-NODAGA-E\[c(RGDyK)\]2
* In case of broncho-pulmonary NET, the subtype must not be small cell lung cancer (SCLC)

Primary outcomes:
measure: uPAR PET/CT imaging of patients with neuroendocrine tumors
timeFrame: 1 hour
Secondary outcomes:
measure: uPAR PET/CT prognostic factor for progression free survival
timeFrame: 12 months
measure: uPAR PET/CT prognostic factor for overall and disease specific survival
timeFrame: 12 months
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet
Study officials:
affiliation: Rigshospitalet, Denmark
name: Esben Carlsen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05381675: Short Term Results of Tele-Rehabilitation
Official title: Short Term Outcomes of Tele-Rehabilitation in Patients With Post-Covid Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: COVID-19
Dyspnea
Keywords: Tele-rehabilitation
COVID-19
Lead sponsor: Harran University
Sponsor class: OTHER
First posted: 2022-05-19
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Most people who have coronavirus disease (COVID-19) recover completely without any sequelae. However, some patients continue to experience symptoms of COVID-19 even though their tests turn negative. This clinical spectrum that occurs after acute infection is called the post-COVID syndrome (PCS). Dyspnea, pain, decreased exercise capacity, limitations in activities of daily living, poor sleep quality, anxiety and depression are common symptoms in PCS. The aim of our study is to examine the effect of tele-rehabilitation-based exercise program on dyspnea, pain, functional capacity, sleep quality, anxiety and depression in individuals with PCS.


Eligibility criteria: Inclusion Criteria:

* Being between the ages of 18-75,
* Being in stable medical condition, conscious and cooperative,
* Having had COVID and continuing symptoms
* Volunteering to participate in the study,
* Own a device that can be connected online independently or with support from family members.

Exclusion Criteria:

SpO2 \< 92%,

* Hypotension (Systolic Blood Pressure \< 90 mmHg or Diastolic Blood Pressure \< 60mmHg)
* Having chronic respiratory disease (COPD, Asthma, etc.)
* Having a stroke or neurodegenerative disease.
* Not being willing to participate in the study

Primary outcomes:
measure: Change from the baseline to the 6th week in mMRC (Modified Medical Research Council) Dyspnoea Scale
timeFrame: Baseline and 6th week
Secondary outcomes:
measure: Change from the baseline to the 6th week in NPRS
timeFrame: Baseline and 6th week
measure: Change from the baseline to the 6th week in the 5 times sit to stand test (5XSST)
timeFrame: Baseline and 6th week
measure: Change from the baseline to the 6th week in the Hospital Anxiety and Depression Scale
timeFrame: Baseline and 6th week
measure: Change from the baseline to the 6th week in the The Pittsburgh Sleep Quality Index
timeFrame: Baseline and 6th week
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: İstanbul University-Cerrahpasa
Study officials:
References: